Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant Mantenimento Immunologico con interleuchina-2 e acido zoledronico in pazienti con Mieloma Multiplo sottoposti a trapianto Autologo di cellule staminali

Trial Profile

Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant Mantenimento Immunologico con interleuchina-2 e acido zoledronico in pazienti con Mieloma Multiplo sottoposti a trapianto Autologo di cellule staminali

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Aldesleukin (Primary) ; Zoledronic acid (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MIMMA
  • Most Recent Events

    • 04 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top